Trial Profile
ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms ADVANCE
- 01 Aug 2022 Primary endpoint has been met (Disease-free survival) , according to Results published in the International Journal of Radiation Oncology, Biology, Physics
- 01 Aug 2022 Results published in the International Journal of Radiation Oncology, Biology, Physics
- 25 Dec 2021 Status changed from recruiting to discontinued.